The use of rituximab therapy improves alveolar macrophage function in patients with autoimmune PAP by reducing anti-GM-CSF antibody levels and promoting resorption of lipoprotein material in the lungs [10]. The gene discussed is CSF2; the disease is autoimmune pulmonary alveolar proteinosis.